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BACKGROUND: Ewing sarcoma is a paradigm of solid tumour -bearing chromosomal translocations resulting in fusion proteins that act
as deregulated transcription factors. Ewing sarcoma translocations fuse the EWS gene with an ETS transcription factor, mainly FLI1.
Most of the EWS–FLI1 target genes still remain unknown and many have been identified in heterologous model systems.
METHODS: We have developed a stable RNA interference model knocking down EWS–FLI1 in the Ewing sarcoma cell line TC71.
Gene expression analyses were performed to study the effect of RNA interference on the genetic signature of EWS–FLI1 and to
identify genes that could contribute to tumourigenesis.
RESULTS: EWS–FLI1 inhibition induced apoptosis, reduced cell migratory and tumourigenic capacities, and caused reduction in tumour
growth. IGF-1 was downregulated and the IGF-1/IGF-1R signalling pathway was impaired. PBK/TOPK (T-LAK cell-originated protein
kinase) expression was decreased because of EWS–FLI1 inhibition. We showed that TOPK is a new target gene of EWS–FLI1.
TOPK inhibition prompted a decrease in the proliferation rate and a dramatic change in the cell’s ability to grow in coalescence.
CONCLUSION: This is the first report of TOPK activity in Ewing sarcoma and suggests a significant role of this MAPKK-like protein kinase
in the Ewing sarcoma biology.
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Ewing sarcoma is an aggressive neoplasm of the bone and soft
tissues of children and young adults. Ewing sarcoma is charac-
terised by the presence of chimeric proteins joining the
NH2-terminal domain of the RNA-binding protein EWS with the
DNA-binding portion of an ETS transcription factor, FLI1, in 90%
of the cases (Delattre et al, 1992; Sorensen et al, 1994; May et al,
1997). There is strong evidence for the oncogenic potential of
EWS–ETS fusions (May et al, 1997). EWS–ETS chimeric proteins
act as deregulated transcription factors, both activating and
repressing the expression of target proteins (Prieur et al, 2004).
Several of these have already been identified, including transcrip-
tion, apoptotic, or signal transduction factors (Dauphinot et al,
2001; Amsellem et al, 2005; Mendiola et al, 2006). The proliferation
and survival of Ewing sarcoma is also determined by autocrine and
paracrine activation of growth factor receptors and their ligands,
such as IGF-1 (Scotlandi et al, 1998).
The cellular context contributes to the phenotype because the
introduction of EWS–ETS fusions into different cellular models
resulted in diverse outcomes ranging from the induction of cell-
cycle arrest or apoptosis to dedifferentiation (Thompson et al,
1999; Deneen and Denny, 2001; Lessnick et al, 2002; Zwerner et al,
2003). The use of RNA interference in the Ewing sarcoma cell lines
allows for a detailed molecular analysis of the targeted gene fusion
and its downstream targets in the tumour context itself, precluding
the use of heterologous model systems.
We have used a stable RNA interference system knocking down
EWS–FLI1 in the Ewing sarcoma cell line, TC71, to establish a
long-term model in which we can analyse in depth the molecular
behaviour of the fusion protein. Our shRNAi model disclosed
TOPK, a kinase involved in cell proliferation and motility, as a new
target of EWS–FLI1. TOPK expression was downregulated because
of fusion interference. EWS–FLI1 inhibition decreased tumouri-
genic potential, reduced the tumour volume in a xenograft model,
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simpaired migration, and rendered cells more sensitive to both
apoptosis and the action of inhibitors of the IGF-1/IGF-1R
pathway, showing the interaction between these two key players
in Ewing sarcoma tumourigenesis.
MATERIALS AND METHODS
Cell lines and drugs
The Ewing sarcoma cell line, TC71, was maintained as described
earlier (Martins et al, 2006). NVP-AEW541 was obtained from
Novartis Pharma AG (Basel, Switzerland). PD-98059 and
LY-294002 were purchased from Stressgen (Victoria, BC, Canada),
and G418 was acquired from Invitrogen (Carlsbad, CA, USA). Cell
lines were tested for the absence of mycoplasma using the
VenorGeM kit (Minerva Biolabs, Berlin, Germany).
shRNAi interference
An shRNAi approach was used based on the pSUPER-neo-GFP
plasmid (Oligoengine, Seattle, WA, USA) (Brummelkamp et al,
2002). The shRNAi sequences were designed to target the fusion
point between EWS and FLI1 following the manufacturer’s
instructions in order to avoid affecting the wild-type partners.
The targeted sequences of EWS–FLI1 were 50-CAGAGCAGCAGCT
ACGGGCAGCAGAACC-30 for 7-6 shRNAi and 50-GGGCAGCAGAA
CCCTTCTT-30 for 7-6 M shRNAi.
The presence of the insert within the recombinant pSUPER
vector was confirmed by sequencing (ABI Prism 3100 Genetic
Analyzer, Applied Biosystems, Foster City, CA, USA).
TC71 cells were electroporated (125V, 800mA, 40–45ms) using
Gene Pulser II (Bio-Rad, Hercules, CA, USA), seeded, and allowed
to recover for 24h. G418 selection (500mgml
 1) was carried
out for 3 weeks, and individual selected clones were grown for
2 additional weeks and split into several plates to create a stock of
the early stage. RNA interference was monitored by analysing
EWS–FLI1 protein and mRNA levels using western blot and
qRT–PCR, respectively. Up to 40 clones were analysed at both
early and late stages (eight cellular passages later).
Validated TOPK siRNA oligos were purchased from Ambion
(Austin, TX, USA). (sense sequence: 50-GGUGAAAAGUCUCUA
AAUGtt-30; antisense sequence: 50-CAUUUAGAGACUUUUCAC
Ctc-30.) TOPK siRNA oligos were transfected using jetPEI
(Polyplus-transfection, Illkirch, France).
Western blot
Western blots were performed as described earlier (Martins et al,
2006). EWS–FLI1 expression was determined using the anti-FLI1
antibody (Santa Cruz BT, Santa Cruz, CA, USA). Other antibodies
used were anti-phospho-p44/p42 MAPK (Thr202/Tyr204), anti-
p44/42 MAPK, anti-phospho-AKT (Ser473), anti-AKT, anti-p57/
Kip2, and anti-Caspase 9 (all from Cell Signaling, Danvers, MA,
USA), anti-DAX1 (a gift from Dr Javier Alonso-IIB, Madrid, Spain),
anti-PARP/Caspase 9 (Serotec Germany, Du ¨sseldorf, Germany),
anti-EWS, anti-IGF-1R and anti-NKX2.2 (Santa Cruz BT), anti-actin
(Sigma, Saint Louis, MO, USA), anti-GAPDH (Stressgen), anti-IGF-1
(Abnova, Taipei, Taiwan), and anti-TOPK (BD, Franklin Lakes, NJ,
USA). The cells were treated with the NVP-AEW541 for 15min and
with the inhibitors for 2h, before IGF-1 stimulation (50ngml
 1)f o r
15min in serum-free conditions.
Quantitative real-time PCR
Quantitative real-time PCR was performed as described
earlier (Martins et al, 2008). Primers for the selected genes were
designed using primer3 software (MIT, Cambridge, MA, USA)
(Supplementary Table 4).
Apoptosis and cell-cycle analysis
Assessment of the apoptotic index and cell-cycle analysis was
made by flow cytometry using the Annexin V–Fitc kit (Immuno-
step, Salamanca, Spain), and IP staining (Sigma) as described
(Martins et al, 2006).
Proliferation assay
To determine the rate of proliferation, we used the 3-(4,
5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
method, as described earlier (Martins et al, 2006). Dose response
under the influence of AEW571, LY294002, or PD98059 was
analysed to determine the IC50 of proliferation. The cells were
incubated with AEW541, LY294002, or PD98059 for 72h on
reaching 40% confluence.
Soft agar assay
Soft agar assay was performed as described earlier (Martins et al,
2006).
Immunohistochemistry
The immunohistochemical study was performed as described
earlier (Mendiola et al, 2006), using a monoclonal anti-DAX1
antibody (clone 2F4; dilution 1:1000).
Motility assay
In all, 10
5 alive cells were counted using a Neubauer chamber
(VWR, West Chester, PA, USA) and seeded per well with IMDM
medium (Invitrogen) without serum in a transwell (BD) of 24-well
plates (Corning, Acton, MA, USA). A volume of the medium
(500ml) was added to the bottom of the well and the plate was
left overnight at 371C and 5% CO2. On the next day, unmigrated
cells in the upper part of the transwell were removed with a cotton
swab and migrated cells in the transwells were fixed in a 4%
paraformaldehyde–PBS solution for 15min. The transwells were
washed three times with PBS 1 , dyed in blue violet solution
(Sigma) for 30min, and rinsed well with water and air-dried.
Membranes of the transwell were cut and deposited individually in
a well of 96-well plates with 300ml of 10% glacial acetic acid
(Merck, Darmstadt, Germany); subsequently, the absorbance was
read at 570nm (Tecan, Ma ¨nnedorf, Switzerland).
Gene expression assays and bioinformatic analysis
Total RNA was extracted, purified, and labelled according to
Affymetrix (Santa Clara, CA, USA) instructions. RNA integrity was
assessed using the Agilent 2100 Bioanalyzer (Agilent, Palo Alto,
CA, USA). Labelled RNA was fragmented and hybridised to the
HU-133A oligonucleotide arrays (Affymetrix). The arrays were
scanned by using the Gene Array Scanner and analysed using the
DNA-Chip Analyzer (Affymetrix). All experiments were performed
in biological duplicates and for both, early (T0) and late passage
(T8). The quality of cRNA was proved using the 30/50 ratios of
housekeeping controls GAPDH and b-actin. Microarray data were
collected and analysed using the bioinformatic software Genetrix
(EpiCenter Software, Pasadena, CA, USA). Genetrix uses the Probe
Profiler package and performs a GeneScreen analysis using Cox
regression. GeneScreen outputs two values for each gene: the first
one is the P-value, which measures the ‘significance of association’
(association with shRNAi or not); the second one is the t-statistic
value, which measures the strength or ‘magnitude of association’.
Lists of the top 300 genes most significantly associated with the
shRNAi clone and the 300 genes that were not associated were
obtained and combined into a single list of 600 probe sets used in a
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shierarchical clustering analysis and to clearly distinguish the
shRNAi clone samples from the others. Genes with a P-value
o0.05 were considered candidate genes.
Chromatin immunoprecipitation (ChIP)
The bioinformatics program, TFM-explorer (http://bioinfo.lifl.fr/
TFME/), was used for searching EWS–FLI1 putative binding sites
in the TOPK promoter and introns. ChIP was performed using the
Magna ChIP G Chromatin Immunoprecipitation kit (Millipore,
Billerica, MA, USA) according to the manufacturer’s instructions.
The antibodies used for each sample were 1mg of IgG-negative
control, 1mg anti-RNA polymerase II antibody-positive control
(provided by the kit), 5.0mg of EWS goat polyclonal IgG (Santa
Cruz BT) – antibody of interest, no antibody–ChIP reaction
containing pre-cleared chromatin, and DNA–protein complexes
before immunoprecipitation, named ‘Input DNA’. As EWS
contains a RNA-binding domain, the immunoprecipitated pro-
ducts corresponded only to the fusion protein (DNA-binding
domain of FLI1) and not to wild-type FLI1. Cell extracts were
sonicated four times with a 12s constant burst (100J energy, 20%
amplitude) (SONICS, Newtown, CT, USA), following by 30–40s
rest on ice between each pulse. Purified DNA was subjected to
PCR. The control human PCR primers used for ChIP were those
described by Zupanska et al (2007). The primers used for probable
TOPK-recognised sequences are detailed in Supplementary Table 5.
The PCR program consisted of 38 cycles of amplification for 20s at
941C, 30s at 581C, and 30s at 721C. An earlier denaturing step of
3min at 941C and a final extension step of 2min were added.
In vivo studies
Four to five-week old female NOD/SCID mice (Charles River,
Barcelona, Spain) were used, following the Spanish and European
Union guidelines (RD 1201/05 and 86/609/CEE, respectively). The
study was approved earlier by the Bioethics Committee of our
institution (CB-A4). Cell suspensions, containing 5 10
6 alive cells
in 0.2ml of 1:1 cellular medium (Matrigel Matrix (BD), were
injected s.c. into the right flank of the mice. Cells were counted
using a Neubauer chamber (VWR) and cellular viability was
checked by trypan blue staining (Sigma). Mice were randomised
into three controls (TC71wt, early mock, and late mock) and two
treated groups (early and late shRNAi clone). Tumours were
measured every 5 days with a caliper, and the diameters were
recorded. Tumour volume was calculated as described earlier
(Martins et al, 2008) by the formula a
2b/6, in which a is the
smallest diameter and b the biggest one. Mice were killed by
anaesthesia overdosing 4 weeks after the cells injection, and
tumours were collected for histopathology analysis.
Statistics
For in vivo studies, one-way ANOVA for independent samples was
performed using the SPSS 15.0 software (SPSS Inc., Chicago, IL,
USA) and mice with a tumour volume higher than 2.5cm
3 were
excluded from the analyses. For comparisons between shRNAi and
mock (early and late stages), we computed two-sided t-tests of
independent samples for each condition.
RESULTS
shRNAi permitted a sustained knockdown of EWS–FLI1
To analyse the effects of a stable suppression of EWS–FLI1
expression in its native context, we used a pSUPER vector that
directs intracellular synthesis of siRNA-like transcripts.
Two different and specific interfering shRNAi (named 7-6 and
7-6 M, respectively), both targeting the fusion point of type 1
EWS–FLI1 mRNA isoform (7-6), were tested in the Ewing sarcoma
cell line, TC71 (Figure 1A). The loss-of-function phenotype was
assessed in selected clones in early and late stages (eight cellular
passages) to confirm the maintenance of the EWS–FLI1 ‘knock-
down’, although a drop in the interference effect was detected
(Figure 1B). Wild-type FLI1 was detected only in the multiple
myeloma cell line MM1S, and its expression was not affected by the
EWS–FLI1 shRNAi constructs. Expression of wild-type EWS
protein was not changed by EWS–FLI1 RNAi, confirming the
specificity of our shRNAi designs (Figure 1C). The effect of RNA
interference was also measured at the mRNA level in the selected
shRNAi clones resulting in 42–54% inhibition (Po0.01), and also
at later passages (Po0.05) (Figure 1D).
These results confirmed the validity and the stable nature of the
shRNAi model through the course of cellular passages.
Stable reduction of EWS–FLI1 prompted an increase in the
apoptotic fraction, and a reduction of the migratory
capacity and tumourigenicity
Up to 40 different TC71 shRNAi clones were obtained. We selected
the one, shRNAi clone 6, showing the most pronounced decrease
in EWS–FLI1 expression, to further characterise and evaluate its
molecular and cellular phenotype.
We observed a marked increase in the apoptotic index of up to
70% in both, early and late stages. Western blotting analysis
confirmed the processing of caspase 9 in the interfered clone in
both stages, although a slight activation could also be seen in the
mock sample, which seemed insufficient for promoting apoptosis
(Figure 2A). PARP was also processed in the shRNAi clone,
confirming caspase cascade activation (data not shown).
To determine whether EWS–FLI1 knockdown affects the ability
of TC71 cells to migrate, we performed a transwell experiment. The
migratory capacity of shRNAi cells was found to be impaired, with
around a 30% decrease in both stages (Figure 2B).
The tumourigenicity of the shRNAi clone was tested using a soft
agar growth assay. The shRNAi cells were largely restricted in their
tumourigenicity, giving rise to fewer and smaller colonies with a
decrease of around 35–40% (Po0.0003) compared with the mock,
which was maintained through the course of cellular passages
(Figure 2C). Similar results were obtained with the shRNAi clone
M2 (data not shown).
Analogous results regarding cell-cycle distribution and apopto-
tic index were obtained using other shRNAi clones in which
interference of EWS–FLI1 expression was less dramatic. There was
a direct relationship between the extent of interference of the
fusion transcript and the degree of change observed, thus
confirming that the effects appearing after EWS–FLI1 inhibition
were due to its specific suppression of expression and not due to
unspecific clonal ‘off-target’ effects (Figure 2D).
The growth rate of these interfered cells was reduced, as
measured by MTT assay, to around 30% in the early passage
(Po0.05). However, this inhibitory effect was lost in the late stage
(Supplementary Figure 1A). Assessment of the cell-cycle pattern of
the shRNAi clone showed no changes in cell-cycle distribution
(Supplementary Figure 1B).
EWS–FLI1 interference reduced tumour growth
We injected in immunodeficient mice cells from the shRNAi clone,
mock, and TC71wt, both in the early and late stages. Tumours
appeared at the same time in all the animals, but mice harbouring
cells from the shRNAi clone in both temporal stages developed
tumours with a marked volume reduction (Figures 3A and B).
Most of the animals injected with the early and late shRNAi clone
cells developed tumours of o0.5 and 0.3cm
3, respectively, with no
tumour reaching 1cm
3 in any case. However, tumours in control
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sgroups (injected with wild-type, early mock cells, and late mock
cells) were markedly larger, most of them close to 1cm
3 or even
larger (Po0.05). Moreover, five animals (two from the wild-type,
two from the early mock, and one from the late mock) developed
tumours between 2.5 and 4.9cm
3 and were not included in the
statistical analyses.
EWS–FLI1 interference downregulated IGF-1 and
sensitised Ewing sarcoma cells to inhibitors of the
IGF-1/IGF-1R signal transduction pathway
We next analysed the effects of EWS–FLI1 interference on the
gene expression signature of the TC71 Ewing sarcoma cells. RNA
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Figure 1 Targeting of EWS–FLI1 through shRNAi for stable protein and mRNA knockdown. (A) Diagram of wild-type EWS, wild-type FLI1, and EWS–
FLI1 fusion type 1. The illustration of EWS–FLI1 cDNA and the location of the two shRNAi designs used, 7-6 and 7-6M, both against fusion break-point.
(B) Analysis by western blotting showed that the EWS–FLI1 expression was reduced in several TC71 shRNAi clones. The EWS–FLI1 reduction is
maintained partially in some shRNAi clones through the course of cellular passages (early and late stages). EWS–FLI1 68kDa, FLI1 51kDa, and actin 42kDa.
3, 4, 5, 6: TC71 shRNAi clones transfected with shRNAi design type 7-6; M2: TC71 shRNAi clone transfected with shRNAi design type 7-6M. MM1S:
multiple myeloma cell line. Positive control for FLI1. NB: neuroblastoma cell line SK-N-JD. Negative control for EWS–FLI1. Actin is shown as a loading
control. (C) Analysis by western blotting showed that the EWS–FLI1 shRNAi designs are specific and did not alter the EWS expression in the early and late
stages. The shRNAi clone corresponds to the TC71 shRNAi clone 6. Actin is shown as a loading control. (D) The shRNAi reduction in the EWS–FLI1
mRNA level assessed through qRT–PCR (SYBR green probes) in the early (T0) and late passage (T8). The shRNAi clone corresponds to the TC71 shRNAi
clone 6. GAPDH was used as an internal control. Columns, mean of triplicates of three different replicates; bars, s.d.
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sfrom the shRNAi clone, mock, and TC71wt from the early and late
stages was isolated and used to perform duplicate hybridisation
experiments with the Affymetrix HG-U133A platform. EWS–FLI1
activated and repressed genes in similar numbers. Several of
the genes identified were previously reported to be repressed
(Supplementary Table 1) or induced (Supplementary Tables 2
and 3) by EWS–FLI1, including p57/Kip2, NXK2.2, and DAX1-
NR0B1. Their expression was validated, confirming the original
microarray data (Supplementary Figures 2A–C, respectively).
As IGF-1 was pointed as a relevant downregulated gene, we
decided to focus on it. Western blot and qRT–PCR analyses
confirmed IGF-1 downregulation (Po0.05) in the shRNAi clone
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Figure 2 The long-term reduction in EWS–FLI1 provoked an increase in the apoptotic fraction, reduced migration capacity, and oncogenic
transformation. There is a direct relationship between the extent of the interference of the fusion transcript and the degree of change observed.
(A) Induction of apoptosis by reduction in the expression of EWS–FLI1 using specific shRNAi in the TC71 Ewing sarcoma cell line in an early and late stage.
The shRNAi clone corresponds to the TC71 shRNAi clone 6. The cells were seeded on 24 well plates, 24h after apoptotic index was determined by FACS
using an annexin V detection kit assay. The means±standard deviations (error bars) of four independent experiments are shown. FACS Apoptotic Analysis
Figures show the various cell populations. A, alive fraction; EA, early apoptosis; LA/N, late apoptosis/necrosis; N, necrosis. x asis: FL3-H Annexin V; y axis:
FL1-H PI. Panel below shows the activation of Caspase 9 in the shRNAi clone in both stages by western Blot. (B) The shRNAi clone cells were less able to
migrate through the matrix of Transwell in both stages, early and late. The shRNAi clone corresponds to the TC71 shRNAi clone 6. A total of 100000 alive
cells were counted using a Neubauer chamber and seeded over the transwell in 24 well-format plates. After 16h, cells of the upper part of the transwell
were scrapped, cells migrated to the bottom part of the transwell were fixed, stained with blue violet solution and discoloured with acetic acid. Absorbance
was measured at 570nm. Photographs of migrated cells taken with a Nikkon 10  objective. Columns, mean of replicates of three different experiments;
bars, s.d. (C) The diminished expression of EWS–FLI impairs the number and size of colonies in the shRNAi clone. The shRNAi clone corresponds to the
TC71 shRNAi clone 6. Colonies were photographed after 2 weeks. Experiments were performed three times with several replicates. (D) The EWS–FLI1
shRNAi extension determined the degree of the changes that were not because of unspecific clonal ‘off-target’ effects. Analysis by western blotting showed
that the EWS–FLI1 expression was reduced in the early stage in both shRNAi clones, 5 and M2, although only shRNAi clone M2 maintained partially EWS–
FLI1 reduction in the late stage. Actin is shown as a loading control. The increase in the apoptotic index was directly correlated to the degree of EWS–FLI1
interference. The shRNAi clone number 5 showed no change in the apoptotic index compared with shRNAi clone M2 that had a more pronounced
inhibition of EWS–FLI1 and showed a increase in its apoptotic fraction. The cells were seeded on 24 well plates, 24h after apoptotic index was determined
by FACS using an Annexin V detection kit assay. The means±standard deviations (error bars) of four independent experiments are shown. Columns, mean
of triplicates of three separate replicates; bars, s.d.
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sduring the course of the cellular passages compared with TC71wt
and mock cells, although a decrease in IGF-1 expression could be
detected in the late stage of the mock because of unknown reasons
(Figures 4A and B). No change in IGF-1R expression was observed
by WB (Figure 4B) or IHC (data not shown). We hypothesised that
the shRNAi clone would be more sensitive to inhibitors of this
signal transduction pathway. NVP-AEW541 is an inhibitor of the
IGF-1 pathway (Garcia-Echeverria et al, 2004). PD98059 and
LY294002 inhibit MEK and PI3-K, respectively, which are key
genes in the IGF-1/IGF-1R pathway. We studied the influence
of NVP-AEW541, PD98059, and LY294002 administration on AKT,
p-AKT, MAPK42/44, and p-MAPK 42/44 levels by WB, and
evaluated the induction of apoptosis and repression of prolifera-
tion. Knockdown of the EWS–FLI1 fusion protein rendered the
shRNAi clone more sensitive to the action of NVP-AEW541,
PD98059, and LY294002, resulting in a lower IC50 for all of them
(Figure 4C). Although the shRNAi clone exhibited a very high
apoptotic level before drug treatment, apoptosis could be further
induced under all conditions by each of the inhibitors (Figure 4D).
AKT and MAPK42/44 phosphorylation was diminished in the
shRNAi clone under IGF-1 stimulation, whereas TC71wt and mock
cells maintained the active phosphorylation status in both kinases
(Figure 4E).
TOPK is a new target of EWS–FLI1 involved in
proliferation
We focused our attention on a new potential target gene of EWS–
FLI1, namely TOPK/PBK (T-lymphokine-activated killer cell-
originated protein kinase). Our gene expression analyses indicated
TOPK as a target gene downregulated as a consequence of EWS–
FLI1 inhibition (score value  6.78 in Genetrix analysis). qRT–PCR
and western blot analysis confirmed a decrease in TOPK at the
mRNA (Po0.05) (Figure 5A) and protein levels (Figure 5A) which
was more intense in the early stage. These results pointed out
TOPK as a candidate EWS–FLI1 target gene.
To confirm this fact we looked for EWS–FLI1-binding sites in
the TOPK proximal promoter and introns using the bioinformatics
program TFM-explorer. Several consensus binding sites were
found confirming TOPK as a putative interacting target of
the fusion gene (TOPK proximal promoter location ( 37: 248),
P-value¼2.20e 02; TOPK intron1 location ( 2197: 2740),
P-value¼7.23e 03). Immunoprecipitation of chromatin with
anti-EWS antibody from mock yielded amplification of the TOPK
intron 1 selected region (Figure 5B). Immunoprecipitation with
IgG or with anti-RNA polymerase II resulted in no amplification of
the TOPK promoter proximal region, intron 1 and intron 4
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s(negative internal control). As a positive control, immunoprecipi-
tation with anti-RNA polymerase II resulted in the amplification
of the G3PDH promoter, without differences between the mock
and the shRNAi clone. We can conclude that TOPK is a target of
EWS–FLI1 because gene fusion binds TOPK intron 1.
We inhibited TOPK expression in TC71wt cells using siRNA
oligos. Seventy-two hours after transfection a reduction in both
TOPK RNA and protein levels was observed (Figure 5C).
A noteworthy effect of TOPK inhibition was a mild decrease in
proliferation rate as measured by MTT (Figure 5D) compared with
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Figure 4 EWS–FLI1 shRNAi impaired the IGF-1/IGF-1R survival pathway and its downstream targets. (A) Histogram representation of IGF-1 transcript
level knockdown in the shRNAi clone as assessed by qRT–PCR normalised to GAPDH. The shRNAi clone corresponds to the TC71 shRNAi clone 6. SYBR
probes were used. All experiments were performed in triplicate in the early and late stages. Columns, mean of triplicates of three different experiments; bars,
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clone 6. Po0.05 values are considered as significant. (E) Effects of NVP-AEW541 combined with inhibitors LY294002 and PD98059 on the activation of the
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sTC71wt and negative siRNA control. A dramatic change in the
growth pattern was detected after knocking down TOPK. TOPK
siRNA cells grew in clumps and were not able to merge as
compared with TC71wt cells (Figure 5D). The decrease in TOPK
levels did not affect the cell-cycle pattern and did not cause an
increase in apoptotic rate (data not shown). Transfection of EWS–
FLI1 type 1 mRNA in the shRNAi clone restored EWS–FLI1
levels; TOPK protein expression was also significantly restored
(Figure 5C). In addition, AKT levels also decreased, thus pointing
to a possible connection between both protein kinases (Figure 5E).
When the expression of TOPK was diminished an increase in the
transcript level of p27/Kip1 was detected (Figure 5E). TOPK
expression could be detected through qRT–PCR in nine Ewing
sarcoma cell lines analysed regardless of the type of EWS–ETS
fusion (Figure 5F).
DISCUSSION
Ewing sarcoma fusion proteins act as aberrant transcription factors by
interfering with different signalling pathways (Prieur et al, 2004).
Identification of EWS–FLI1 targets represents a key aspect in the
understanding of the molecular behaviour of Ewing sarcoma. RNA
interference has been shown to be a powerful tool that allows targeting
chimeric oncogenes and gaining a deeper knowledge of tumour
biology in its own context (Sharp, 1999; Tijsterman et al,2 0 0 2 ) .
Ectopic expression models for the study of gene fusions are
disadvantageous as they do not account for the true cellular
context. A wide variety of effects have been documented after
EWS–FLI1 induction in heterologous models, ranging from
dedifferentiation to growth arrest (Kovar, 2005).
shRNAi studies to suppress EWS–FLI1 in the Ewing sarcoma
cells have been carried out using different systems (Siligan et al,
2005; Kinsey et al, 2006; Owen and Lessnick, 2006; Carrillo et al,
2007; Stegmaier et al, 2007). Our shRNAi approach, based on the
pSUPER vector, targets at the junction point of EWS–FLI1 type 1
fusion transcripts in a reliable model, the Ewing sarcoma cell line,
TC71. The effects due to EWS–FLI1 interference were observed in
different clones and were related to the degree of fusion inhibition,
indicating a direct and specific correlation. We reported a
significant reduction in EWS–FLI1 expression, which was main-
tained through several cellular passages, confirming the validity of
our approach, although a partial loss of RNA interference was
detected through the course of cellular passages as also described
by other group (Smith et al, 2006) in the Ewing sarcoma cell line
A673.
The main consequence observed in our model because of the
silencing of EWS–FLI1 was a strong induction of apoptosis,
correlating with caspase 9 pathway activation and PARP proces-
sing. EWS–FLI1 interference has been documented to increase
remarkably the number of apoptotic cells (Prieur et al, 2004).
A decrease in the anchorage-independent capacity to grow has also
been reported (Smith et al, 2006). The ability of cells to grow
in semisolid media was also affected in our shRNAi model.
Disruption of EWS–FLI1 provoked the appearance of fewer and
smaller colonies mainly in the early stage. EWS–FLI1 reduction
also impaired migration capacity. CCN3 (NOV) has been described
as an important mediator of migration and invasion (Benini et al,
2005) and its expression was downregulated in our model; this
could explain loss of function of interfered cells although it is not
possible to rule out the contribution of early apoptosis to that
observation.
NOD/SCID mice injected with shRNAi cells in both temporal
stages developed tumours with a significant reduction in tumour
volume with respect to mock and TC71wt. shRNAi cells had
restricted their tumourigenicity and migratory capacity, which
could explain the tumour growth reduction observed. Tumoural
growth reduction in nude xenograft models has been described in
several studies either using an shRNAi model (Smith et al, 2006) or
through the inhibition of EWS–FLI1 targets such as IGF-1/IGF-1R
(Scotlandi et al, 1998), VEGF (Guan et al, 2005), NR0B1/DAX1
(Kinsey et al, 2006), and cholecystokinin (Carrillo et al, 2007).
The strong decrease in IGF-1 gene expression observed after
EWS–FLI1 silencing was analysed. The IGF-1/IGF-1R signal
transduction pathway is over-expressed in many sarcomas
(Sekyi-Otu et al, 1995) and has great relevance for the biology of
Ewing sarcoma (Scotlandi et al, 1996). Blocking IGF-1/IGF-1R has
shown its effectiveness in restricting tumoural growth (Martins
et al, 2006). Our shRNAi clone showed an increased sensitivity to
the action of IGF-1/IGF-1R pathway inhibitors NVP-AEW541,
LY294002, and PD98059, and a reduction in the phosphorylation
levels of AKT and MAPK 42/44. IGF-1R protein status is not
affected, and therefore the effects observed were due to IGF-1
downregulation. This observation underlines the fact that IGF-1/
IGF-1R signalling activation and EWS–FLI1 fusion are two key
molecular features in Ewing sarcoma and suggests the need for
blocking both of them in order to achieve therapeutical benefits.
Understanding the oncogenic properties of EWS–FLI1 requires
identification of the downstream targets. The aim of our gene
expression analysis was to identify potentially regulatory genes,
whose transcript levels change in response to oncoprotein
inhibition. Well-known EWS–FLI1 targets were among the genes
identified, including NR0B1/DAX1, zyxin, p57/Kip2, and NKX2.2
(Dauphinot et al, 2001; Amsellem et al, 2005; Mendiola et al, 2006;
Smith et al, 2006), confirming the validation of our stable shRNAi
model.
We have mainly focused our attention on a new target gene of
EWS–FLI1, TOPK/PBK. TOPK, T-lymphokine-activated killer cell-
originated protein kinase, is a 36-kDa protein located on 8p21.2
belonging to the Ser/Thr protein kinase family. It was cloned as a
new MAPKK-like protein kinase, highly conserved among
vertebrates, specifically expressed in the testis, placenta, activated
lymphoid cells, and neural lineages (Abe et al, 2000; Dougherty
et al, 2005). TOPK has been involved in haematological
malignancies (Simons-Evelyn et al, 2001; Nandi et al, 2004), in
breast cancer (Park et al, 2006), in preventing apoptosis in a
melanoma cell line (Zykova et al, 2006), as a proliferative agent
related to DNA damage response through p38 MAPK, c-Jun-NH2-
Kinase1, and H-Ras signalling (Ayllon and O’Connor, 2007; Oh
et al, 2007), and as an enhancer of Cdk1/cyclin B1-dependent
phosphorylation of PRC1 and promoter of cytokinesis (Abe et al,
2007). Our gene expression analysis pointed out TOPK as a target
gene downregulated because of EWS–FLI1 inhibition. TOPK
reduction at protein and mRNA levels was confirmed through
WB and qRT–PCR, respectively, and was maintained during
cellular passages.
Using an in silico approach, we analysed the TOPK promoter
and introns in order to find EWS–FLI1 binding sites. EWS–FLI1
and some ETS family members, such as wild-type FLI1, require a
9-bp consensus sequence harbouring a GGAA ‘core’. A 9-bp
sequence, GAAGGAAGT, was found in the TOPK intron 1, which
showed limited similarity to the high-affinity ETS-binding
consensus (ACCGGAAGT) (Gangwal and Lessnick, 2008). It has
been shown in promyelocytic leukaemia cells that the transcrip-
tional control of TOPK promoter is mostly because of binding of
transcription factors E2F and CREB/ATF to two distinct binding
sites within it (Nandi and Rapoport, 2006). TOPK intron 1 showed
an EWS–FLI1 binding site as validated by ChIP, probably
corresponding to the above-mentioned ETS binding sequence.
We also found E-box sequences that are high-affinity c-Myc-
binding sites (CACATG at  574 and  3098), suggesting that
c-Myc, an EWS–FLI1 target, could play a role in the transcrip-
tional activation of the TOPK promoter.
Downregulation of TOPK activity was achieved in the Ewing
sarcoma cell line, TC71, using RNAi oligos. TOPKsi cells showed a
dramatic change in growth pattern caused presumably by TOPK
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sinhibition; TOPK-interfered cells seemed to be disabled in their
ability to reach confluence compared with TC71wt cells. The same
observation was described earlier when TOPK was knocked down
using siRNA oligos in the prostate carcinoma cell line, DU145
(Ayllon and O’Connor, 2007). The main consequence observed
because of TOPK inhibition was a 35% reduction in the
proliferation rate. The results were concordant with the significant
suppression of cell growth caused by TOPK interference in human
breast cancer and colorectal cell lines (Park et al, 2006; Zhu et al,
2007). Surprisingly, TOPK silencing raised AKT levels. When
EWS–FLI1 expression was restored in the shRNAi clone, the
TOPK level also recovered and AKT level decreased to the level
observed in TC71wt, thus proving that AKT increase was due to
the TOPK knockdown and not due to EWS–FLI1 interference.
AKT is a relevant gene in the Ewing sarcoma biology that is
involved in proliferation and survival, and the therapeutical benefit
of its inhibition is clear (Martins et al, 2006); further research to
clarify the relationship between TOPK and AKT needs to be
carried out. Neither cell-cycle pattern nor apoptotic index was
modified after TOPK silencing, as was the case in the MCF-10A
breast epithelial cell line (Ayllon and O’Connor, 2007), although
the levels of p27/Kip1, a gene described in Ewing sarcoma by its
expression level inversely correlated with that of EWS–FLI1
(Matsunobu et al, 2006), were increased.
In this study, we have developed a stable RNAi model system.
Our shRNAi model maintained the EWS–FLI1 knockdown
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sthrough the course of the cellular passages, showing that it is a
valid one for assessing the long-term effects of EWS–FLI1
interference. EWS–FLI1 interference caused a decrease in IGF-1
levels and rendered cells more sensitive to the action of inhibitors
of the IGF-1/IGF-1R pathway, pointing to the importance of this
survival pathway and the necessity to block it for therapeutic
benefits. Our model could be a valuable tool for confirming targets
already described and for discovering new ones such as TOPK, a
kinase involved in proliferation and motility. This is the first time
that TOPK expression is described in Ewing sarcoma, and the
changes observed after TOPK interference were concurrent with
those observed in other cellular models, confirming the relevant
role of this gene in the Ewing sarcoma biology.
ACKNOWLEDGEMENTS
We thank Dr Iranzu Gonza ´lez, Universidad de Navarra, Pamplona,
Spain, for the TC71 cell line, Novartis Pharma AG, Basel,
Switzerland, for providing us NVP-AEW541, Dr Miguel Alaminos,
from the Department of Histology, School of Medicine-Universi-
dad de Granada, Granada, Spain, for helpful comments regarding
RNAi design, Dr Javier Alonso, from IIB, CSIC/UAM, Madrid,
Spain, for giving us DAX1/NR0B1 antibody, Dr Juan Pedro
Bolan ˜os from INCYL, Universidad de Salamanca, Salamanca,
Spain, for providing us the pSUPER plasmid, and the Diagnostic
Molecular Pathology Laboratory of CIC for immunohistochemistry
and tissue processing of the animal model. CIC-IBMCC and HHU
belong to NoE Eurobonet, FP6-2004-Lifescihealth-5, proposal
number 018814, European Commission. Work at CIC is also
funded by Instituto de Salud Carlos III, Spanish Ministry of
Science and Innovation-FEDER (PI052524; RD06/0020/0059, CD6/
00001). Herrero-Martı ´n was a recipient of a pre-doctoral fellowship
from the Departamento de Educacio ´n, Junta de Castilla y Leo ´n,
Spain. This work has been done within the Accio ´n Transversal en
Ca ´ncer program and the cooperative agreement between ISCIII
and FICUS.
Conflict of interest
The authors declare no conflict of interest.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
REFERENCES
Abe Y, Matsumoto S, Kito K, Ueda N (2000) Cloning and expression of
a novel MAPKK-like protein kinase, lymphokine-activated killer T-cell-
originated protein kinase, specifically expressed in the testis and
activated lymphoid cells. J Biol Chem 275: 21525–21531
Abe Y, Takeuchi T, Kagawa-Miki L, Ueda N, Shigemoto K, Yasukawa M,
Kito K (2007) A mitotic kinase TOPK enhances Cdk1/cyclin B1-depen-
dent phosphorylation of PRC1 and promotes cytokinesis. J Mol Biol
370: 231–245
Amsellem V, Kryszke MH, Hervy M, Subra F, Athman R, Leh H,
Brachet-Ducos C, Auclair C (2005) The actin cytoskeleton-associated
protein zyxin acts as a tumour suppressor in Ewing tumour cells.
Exp Cell Res 304: 443–456
Ayllon V, O’Connor R (2007) PBK/TOPK promotes tumour cell prolifera-
tion through p38 MAPK activity and regulation of the DNA damage
response. Oncogene 26: 3451–3461
Benini S, Perbal B, Zambelli D, Colombo MP, Manara MC, Serra M, Parenza
M, Martinez V, Picci P, Scotlandi K (2005) In Ewing’s sarcoma
CCN3(NOV) inhibits proliferation while promoting migration and
invasion of the same cell type. Oncogene 24: 4349–4361
Brummelkamp TR, Bernards R, Agami R (2002) A system for stable expres-
sion of short interfering RNAs in mammalian cells. Science 296: 550–553
Carrillo J, Garcia-Aragoncillo E, Azorin D, Agra N, Sastre A, Gonzalez-
Mediero I, Garcia-Miguel P, Pestana A, Gallego S, Segura D, Alonso J
(2007) Cholecystokinin down-regulation by RNA interference impairs
Ewing tumour growth. Clin Cancer Res 13: 2429–2440
Dauphinot L, De Oliveira C, Melot T, Sevenet N, Thomas V, Weissman BE,
Delattre O (2001) Analysis of the expression of cell cycle regulators in
Ewing cell lines: EWS-FLI-1 modulates p57KIP2and c-Myc expression.
Oncogene 20: 3258–3265
Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, Kovar H,
Joubert I, de Jong P, Rouleau G, Aurias A, Thomas G (1992) Gene fusion
with an ETS DNA-binding domain caused by chromosome translocation
in human tumours. Nature 359: 162–165
Deneen B, Denny CT (2001) Loss of p16 pathways stabilizes EWS/FLI1
expression and complements EWS/FLI1 mediated transformation.
Oncogene 20: 6731–6741
Dougherty JD, Garcia AD, Nakano I, Livingstone M, Norris B, Polakiewicz
R, Wexler EM, Sofroniew MV, Kornblum HI, Geschwind DH (2005) PBK/
TOPK, a proliferating neural progenitor-specific mitogen-activated
protein kinase kinase. J Neurosci 25: 10773–10785
Gangwal K, Lessnick SL (2008) Microsatellites are EWS/FLI response
elements: genomic ‘junk’ is EWS/FLI’s treasure. Cell Cycle 7: 3127–3132
Figure 5 Identification and characterisation of TOPK as a new EWS–FLI1 target. (A) The histogram representation of TOPK mRNA level reduction in
the shRNAi clone as assessed by qRT–PCR normalised to GAPDH. SYBR probes were used. All experiments were performed in triplicate in an early and
late stage. Columns, mean of triplicates of three separate determinations; bars, s.d. The TOPK protein level is reduced in the shRNAi clone in the early and
late stages as determined through western blot. Actin was used as a loading control. The shRNAi clone corresponds to the TC71 shRNAi clone 6.
(B) EWS–ChIP. EWS–FLI1 binds TOPK intron 1. The figure shows amplicons resulting from immunoprecipitation with IgG (negative control), anti-RNA
polymerase II antibody (positive control), anti EWS monoclonal antibody (specific), or input DNA (pre-cleared chromatin, no antibody) from mock clone.
Primers for TOPK intron 4 were used as internal negative control. (C) The TOPK mRNA expression level decrease in TC71 TOPK siRNA cells (72h after
transfection) assessed by qRT–PCR normalised to GAPDH (TC71 C-siRNA as negative control). SYBR probes were used. Experiments were performed in
triplicate. Columns, mean of triplicates of three separate determinations; bars, s.d. Protein level of TOPK determined by western blot. TOPK siRNA effectively
diminished the TOPK protein levels with respect to the untransfected TC71wt cell line. Actin was used as a loading control. Western blot showing the
TOPK protein levels restored after transfection of EWS–FLI1 type 1 fusion into the shRNAi clone. The shRNAi clone corresponds to the TC71 shRNAi
clone 6. Actin was used as a loading control. (D) Proliferation index measured through MTT assay. The TOPK interference (48 and 72h after transfection)
caused a significant decrease in growth rate at 72h compared with TC71wt and negative siRNA control (data not shown). Columns, mean of replicates of
three different replicates; bars, s.d. The morphological changes of TC71 TOPKsi RNA cells respect the TC71wt (72h after transfection). Cells were unable to
reach confluence and formed clumps. (E) The p27/Kip1 mRNA expression level increases in TC71 TOPK siRNA cells assessed by qRT–PCR normalised to
GAPDH (TC71 C-siRNA as negative control). SYBR probes were used. Experiments were performed in triplicate. Columns, mean of triplicates of three
different experiments; bars, s.d. Western blot showing the AKT protein level increase in TOPKsi cells compared with TC71wt and shRNAi clone transfected
with EWS–FLI1 type 1 fusion. Actin was used as a loading control. The shRNAi clone corresponds to the TC71 shRNAi clone 6. (F) Relative expression
value of TOPK mRNA in nine different Ewing sarcoma cell lines determined by qRT–PCR normalised to GAPDH. SYBR probes were used. Experiments
were performed in triplicate. Columns, mean of triplicates of three different experiments; bars, s.d.
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